Not Yet RecruitingPhase 2/3

Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

China750 participantsStarted 2026-03-17

Plain-language summary

The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age is 18 years old or above.
✓. Diagnosed as anterior circulation large vessel occlusion stroke by CTA, MRA or DSA.
✓. Randomized within 24h after the onset.
✓. The NIHSS score is above 5 and the ASPECT score is above 3 points while receiving imaging examination;
✓. The mTICI score after endovascular treatment (EVT) is above 2b.
✓. informed consent.

Exclusion criteria

✕. Intracranial hemorrhage confirmed by CT or MRI.
✕. mRS score\>2 for patients \<80 years, or mRS score\>1 for those ≥80 years before onset.
✕. Pregnant or lactating women.
✕. Allergic to contrast agents.
✕. Allergic to baricitinib or having contraindications for using baricitinib.
✕. Participating in other clinical studies.
✕. Systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg, and unable to be controlled by oral antihypertensive drugs.
✕. Genetic or acquired bleeding diathesis, lack of anticoagulant factors or having taken oral anticoagulants and INR \>1.7.

What they're measuring

Distribution of 90-day mRS scores

Timeframe: 90±14 days post-procedure

Trial details

NCT IDNCT07449910

SponsorThe First Affiliated Hospital of University of Science and Technology of China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-17

Contact for this trial

Wei Hu, MD, PhD

+86 055162284313 andinghu@ustc.edu.cn

View on ClinicalTrials.gov More Acute Ichemic Stroke trials